1. Home
  2. NUVB vs SLQT Comparison

NUVB vs SLQT Comparison

Compare NUVB & SLQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • SLQT
  • Stock Information
  • Founded
  • NUVB 2018
  • SLQT 1999
  • Country
  • NUVB United States
  • SLQT United States
  • Employees
  • NUVB N/A
  • SLQT N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • SLQT Specialty Insurers
  • Sector
  • NUVB Health Care
  • SLQT Finance
  • Exchange
  • NUVB Nasdaq
  • SLQT Nasdaq
  • Market Cap
  • NUVB 1.1B
  • SLQT 343.7M
  • IPO Year
  • NUVB N/A
  • SLQT 2020
  • Fundamental
  • Price
  • NUVB $3.28
  • SLQT $2.03
  • Analyst Decision
  • NUVB Strong Buy
  • SLQT Hold
  • Analyst Count
  • NUVB 6
  • SLQT 2
  • Target Price
  • NUVB $8.17
  • SLQT $4.38
  • AVG Volume (30 Days)
  • NUVB 6.7M
  • SLQT 2.7M
  • Earning Date
  • NUVB 11-05-2025
  • SLQT 11-03-2025
  • Dividend Yield
  • NUVB N/A
  • SLQT N/A
  • EPS Growth
  • NUVB N/A
  • SLQT N/A
  • EPS
  • NUVB N/A
  • SLQT 0.01
  • Revenue
  • NUVB $14,355,000.00
  • SLQT $1,526,594,000.00
  • Revenue This Year
  • NUVB $332.80
  • SLQT $13.85
  • Revenue Next Year
  • NUVB $360.12
  • SLQT $13.64
  • P/E Ratio
  • NUVB N/A
  • SLQT $152.65
  • Revenue Growth
  • NUVB 900.35
  • SLQT 15.50
  • 52 Week Low
  • NUVB $1.54
  • SLQT $1.62
  • 52 Week High
  • NUVB $4.09
  • SLQT $6.86
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 58.18
  • SLQT 45.69
  • Support Level
  • NUVB $3.20
  • SLQT $1.99
  • Resistance Level
  • NUVB $3.41
  • SLQT $2.16
  • Average True Range (ATR)
  • NUVB 0.27
  • SLQT 0.12
  • MACD
  • NUVB -0.03
  • SLQT -0.02
  • Stochastic Oscillator
  • NUVB 33.55
  • SLQT 23.17

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About SLQT SelectQuote Inc.

SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.

Share on Social Networks: